Viking Therapeutics Inc. (VKTX)
VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug
Viking Therapeutics climbs after it completes enrollment in the second phase III obesity study for VK2735 and advances its bid in a fast-growing, competitive weight-loss market.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.17, denoting a -1.17% move from the preceding trading day.
Why Is Viking Therapeutics (VKTX) Up 16.3% Since Last Earnings Report?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
Viking Therapeutics, Inc. (VKTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Viking Therapeutics, Inc. (VKTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
Viking Therapeutics, Inc. (VKTX) closed at $31.51 in the latest trading session, marking a -1.96% move from the prior day.
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today
Viking Therapeutics, Inc. (VKTX) reached $33.84 at the closing of the latest trading day, reflecting a +2.64% change compared to its last close.
Viking Therapeutics: Full-Speed Ahead
Viking Therapeutics is aggressively advancing its GLP-1 pipeline, with two pivotal Phase 3 trials now underway or imminent. VKTX's Phase 2 oral data showed up to 14.7% weight loss in 13 weeks, positioning it competitively against current market leaders. With a $3.5B market cap and $706M cash, VKTX trades at a compelling discount to recent sector M&A benchmarks.
VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates
Viking Therapeutics posts a wider-than-expected Q4 loss, but shares jump as it advances oral VK2735 into late-stage obesity studies.
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
Viking Therapeutics plans to advance oral obesity drug to late-stage trial
Viking Therapeutics said on Wednesday that it plans to test its experimental oral obesity drug in a late-stage study later this year.
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $29.06, signifying a -3.9% move from its prior day's close.
Viking Therapeutics to Report Q4 Earnings: Here's What to Know
VKTX heads into Q4 earnings with investor focus on VK2735's late-stage obesity studies that are witnessing rapid enrollment momentum.
